Framingham-based AB SCIEX, a global analytical technology company, announced the launch of a series of spectrometry-based systems for use in European clinical diagnostic laboratories, the company said.
The series, known as 3200MD, is the company’s first of a family of in vitro diagnostic devices designed to identify inorganic and organic compounds in human specimens for clinical use, according to the company.
After meeting regulatory requirements in Europe, AB SCIEX will continue to roll out the series in other countries, the company said.
